MedTrace Logo

Treatment of Bile Acid Malabsorption With Liraglutide

NCT03955575 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-06-03

No results posted yet for this study

Summary

Comparing the effect of Liraglutide on bile acid malabsorption, with colesevelam

Conditions

  • Bile Acid Malabsorption

Interventions

DRUG

Liraglutide 6 MG/ML

Liraglutide as injections.

DRUG

Colesevelam

3 x 625 miligram 2 times a day.

Sponsors & Collaborators

  • Herlev and Gentofte Hospital

    collaborator OTHER

  • Filip Krag Knop

    lead OTHER

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-07
Primary Completion
2021-03-10
Completion
2022-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03955575 on ClinicalTrials.gov